CLASS II ONGOING Drug recall · Reported 19 Jun 2024 · FDA Enforcement Report

Drug Vial Label: Zilretta¿ recalled by Pacira Pharmaceuticals

Pacira Pharmaceuticals is recalling Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable, distributed nationwide in the US. The recall was initiated on 7 May 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: 082657 (kit 23-9004), Exp: July 2024.
NDC65250-003
Quantity recalled43,768 kits

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0546-2024
FDA event ID
94568
Recalling firm
Pacira Pharmaceuticals, San Diego, CA
Manufacturer
Pacira Pharmaceuticals, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
7 May 2024
FDA classified
7 Jun 2024
Reported
19 Jun 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

7 May 2024Recall initiated by company
7 Jun 2024Classified by FDA+31 days
19 Jun 2024Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-001-01. Diluent Vial Label: Diluent, 5mL, Sterile single use, Rx only, Manufactured for Pacira Pharmaceuticals Inc., NDC 65250-002-01. Carton Label: Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01.

Where it was distributed

U.S. Nationwide.

Nationwide

Questions about this recall

Why was it recalled?

Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.

Which lots are affected?

Lot: 082657 (kit 23-9004), Exp: July 2024.

Where was it sold?

U.S. Nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Pacira Pharmaceuticals

All 4

Other Triamcinolone Acetonide recalls

All 26